



**Fiona du Monceau**

**Executive Vice President Patient Evidence**

**Appointed in 2024**

**Date of birth: 1978**

**Nationality: Belgian**

**Introduction & Professional experience**

Fiona du Monceau is a member of UCB's Executive Committee since April 2024, serving as Executive Vice President Patient Evidence. As such she is responsible for the late-stage clinical development of UCB's new molecules, brand positioning and strategy, medical affairs, and the interaction with key external stakeholders such as government regulators, patient organizations or public officials. Fiona brings extensive expertise of the pharmaceutical industry and has a proven leadership track record. Before taking on her executive role within UCB, Fiona du Monceau was a member of the Board of Directors of UCB since 2021, resigning in March 2024 to take her new responsibilities within the company.

Fiona du Monceau was from June 2020 until recently, COO and CFO of ExeVir Bio, a spin out of the VIB. She led the spin out, built up the company, its pipeline and brought the first lead asset from research to clinic through a Phase 1a and Phase 1b/2a in less than 18 months. She raised a total of €85Million in equity, non-dilutive funding and venture debt.

Prior to this, Fiona worked for UCB Ventures as a Venture Partner. UCB Ventures is a €150 million strategic corporate venture fund which was set up to invest in innovative, longer term and higher risk opportunities beyond UCB's current focus areas. Her UCB career began in 2014 when she was appointed as Bone Global Commercial Lead and Head of EU, Bone.

Fiona has previously worked in Business Development for GlaxoSmithKline Biologicals in Belgium. In 2002, she moved to the US and worked at McKinsey & Company, based in their New Jersey office, covering healthcare clients in the US and Europe. From 2006 to 2014, she held several leadership roles at Eli Lilly contributing to the launches, new indications and relaunches of several drugs across different therapeutic areas (Neurology, Cardiovascular, Osteoporosis and Immunology), working with alliance



partners, managing patient support programs and leading organizational changes through patent exclusivities and new models.

Fiona du Monceau was previously a member of the Board of Directors of Financière de Tubize from 2014 until March 2024, a Board member of the company Medifin, a medical imaging unit prior to its acquisition and served as a governor of the London Business School including being a member of its audit and risk committee.

Fiona is Belgian, married and has four children.

### **Education**

Fiona graduated with a MSc in Management from the Solvay Business School (ULB) and an MBA from Harvard Business School (2006). She is a Fulbright Scholar and a recipient of a Belgian American Education Foundation (BAEF) scholarship. She also followed a Digital Marketing Leadership Program with Squared Online in 2014.

